Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.58 USD
-0.02 (-1.25%)
Updated Aug 7, 2025 11:03 AM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATNM 1.58 -0.02(-1.25%)
Will ATNM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Other News for ATNM
Actinium Pharmaceuticals (ATNM) Showcases Promising Prostate Cancer Treatment Data
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer ...
Actinium Pharmaceuticals' ATNM-400 shows improved survival in prostate cancer
Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals
Actinium Pharma (ATNM) Rating Reaffirmed with Stable Price Target | ATNM Stock News